Please Wait
Applying Filters...
menu
    • menu
    Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    Cilastatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,465Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Labeler NDC Package Code Non Proprietary Name Start Marketing Date End Marketing Date Category Code Dosage Form (Strength)
    28/03/2025 Merck & Co
    U.S.A
    		 Merck Sharp & Dohme LLC 0006-0138 IMIPENEM ANHYDROUS, cilastatin, and RELEBACTAM ANHYDROUS 2020-01-06 2025-12-31 DRUG FOR FURTHER PROCESSING INJECTION, POWDER, FOR SOLUTION (500mg/100mL 500mg/100mL 250mg/100mL)